摘要
目的观察尤瑞克林联合丁苯酞治疗老老年急性脑梗死患者的临床疗效及用药安全性。方法将中国人民解放军联勤保障部队第980医院神经内科及干部病房2021年6月至2023年1月收治的105例老老年急性脑梗死患者按随机数字表法分为对照组、观察1组(尤瑞克林组)、观察2组(尤瑞克林+丁苯酞组),每组各35例。3组患者均给予基础治疗,观察1组在常规治疗基础上给予尤瑞克林治疗,观察2组在常规治疗基础上给予尤瑞克林联合丁苯酞治疗。观察3组患者治疗的总有效率,美国国立卫生研究院卒中量表(NIHSS)评分、简易精神状态检查量表(MMSE)评分、Barthel指数、神经元特异性烯醇化酶(NSE)水平、C反应蛋白(CRP)水平、红细胞比容及不良反应发生率。比较3组患者治疗后的临床疗效及老老年患者用药的安全性。结果与对照组相比,观察1组、观察2组治疗后总有效率明显提高;NIHSS评分、MMSE评分、Barthel指数明显改善;CRP、NSE、红细胞比容均有明显降低,差异均有统计学意义(P<0.05)。观察2组与观察1组相比较,各项指标均有明显提升,差异均有统计学意义(P<0.05),且不良反应发生率差异无统计学意义(P>0.05)。结论尤瑞克林联合丁苯酞治疗老老年急性脑梗死,可有效改善临床症状,提高临床治疗效果,安全性好。
Objective To observe the clinical efficacy and safety of urinary kallidinogenase combined with butylphthalide in the treatment of very elderly patients with acute cerebral infarction.Methods A total of 105 elderly patients with acute cerebral infarction admitted to the Department of Neurology and Cadre Ward of the 980th Hospital of the Joint Logistics Support Force of the Chinese People’s Liberation Army from June 2021 to January 2023 were randomly divided into control group,observation group 1(urinary kallidinogenase group),and observation group 2(urinary kallidinogenase+butylphthalide group),with 35 cases in each group.The three groups were given basic treatment.The observation group 1 received was treated with urinary kallidinogenase on the basis of routine treatment,and the observation group 2 was treated with urinary kallidinogenase combined with butylphthalide on the basis of routine treatment.The total effective rate of treatment,National Institutes of Health Stroke Scale(NIHSS)score,Mini-mental State Examination(MMSE)score,Barthel index,neuron-specific enolase(NSE),C-reactive protein(CRP),hematocrit and incidence of adverse reactions were observed in the three groups.The clinical efficacy of the three groups after treatment and the safety of medication in elderly patients were compared.Results Compared with the control group,the total effective rate of the observation group 1 and the observation of group 2 was significantly improved after treatment.NIHSS score,MMSE score and Barthel index were significantly improved.CRP,NSE and hematocrit were significantly decreased.The differences were statistically significant(P<0.05).Compared with the observation group 1,the indexes of the observation group 2 were significantly improved,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions(P>0.05).Conclusion Urinary kallidinogenase combined with butylphthalide in the treatment of elderly patients with acute cerebral infarction can effecti
作者
马丽苹
矫树生
王晓鹏
MA Liping;JIAO Shusheng;WANG Xiaopeng(Department 2,Cadre Ward,980th Hospital of the Joint Logistics Support Force of the People’s Liberation Army of China,Shijiazhuang,Hebei 050000,China;Department of Neurology,980th Hospital of the Joint Logistics Support Force of the People’s Liberation Army of China,Shijiazhuang,Hebei 050000,China;Department of Neurology,Second Affiliated Hospital of Hebei Medical University,Shijiazhuang,Hebei 050000,China)
出处
《重庆医学》
CAS
2023年第20期3088-3092,共5页
Chongqing medicine
基金
河北省重点科技研究计划项目(20180915)。
关键词
尤瑞克林
丁苯酞
老老年
急性脑梗死
安全性
eureklin
butylphthalide
elderly people
acute cerebral infarction
security
